Gilead to Donate Experimental Coronavirus Drug for 140,000 Cases

In this article

We’re tracking the latest on the coronavirus outbreak and the global response. Sign up here for our daily newsletter on what you need to know.

Gilead Sciences Inc. said it’s donating 1.5 million doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients.

The drug will be offered for “compassionate use” and will treat patients with severe symptoms, Chairman and Chief Executive Officer Daniel O’Day said in an open letter. The company is also boosting its supply of remdesivir to more than 500 treatment courses by October, and to more than 1 million by the end the year. Production time has also been accelerated to six months from one year, he said.

“While we are working with the utmost sense of urgency on the immediate needs before us, we are also looking forward,” he said. “Over the next weeks and months, we will be able to further increase our supplies of remdesivir as raw materials with long lead times become available for manufacture.”

32,133 in U.S.Most new cases today

-26% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23

-1.​138 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23


The drugmaker said last week it’s switching to “expanded access” from a “compassionate use” program under which remdesivir was given to more than 1,000 Covid-19 patients. The move will accelerate its emergency use for multiple severely ill patients.

A World Health Organization panel said in January that remdesivir was considered to be the most promising therapeutic candidate based on its broad antiviral spectrum, and existing data based on human and animal studies. The medication was developed initially for Ebola and studied in patients in Eastern Congo.

Multiple clinical trials are investigating the drug’s effects in Covid-19 patients in China and elsewhere.

Gilead Expands Access to Experimental Coronavirus Drug

Source: Read Full Article